What do we really know about VBID? Quality of the evidence and ethical considerations for health plan sponsors

Journal of Managed Care Pharmacy

Volumn 17, Issue 2, 2011, Pages 156-174

  Fairman, Kathleen A ^a   Curtiss, Frederic R ^b  

^a Academy of Managed Care Pharmacy   (United States)

^b Journal of Managed Care Pharmacy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CANCER SCREENING; CONSUMER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DYSLIPIDEMIA; EDITORIAL; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; FUNDING; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEALTH SERVICE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; IMPLANT; INFORMATION PROCESSING; MAMMOGRAPHY; MEDICAL ETHICS; MEDICAL INFORMATION; MEDICAL RESEARCH; META ANALYSIS (TOPIC); PHARMACY; PRESCRIPTION; QUALITY CONTROL; STROKE; STUDY DESIGN; VALUE BASED INSURANCE DESIGN;

EID: 79952609487     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2011.17.2.156     Document Type: Editorial

References (88)

1. Agency for Healthcare Research and Quality. Filling the information needs for healthcare reform: expert meeting summary and identification of next steps. Available at: http://www.ahrq.gov/data/hinfosum.htm. Accessed January 24, 2011.
2. Diamond Management & Technology Consultants. The Health Care Reform Survey 2010. Willis. November 10, 2010. Available at: http://www.willis.com/documents/publications/Services/Employee_Benefits/Health_Care_Reform_Survey_2010_V9.pdf. Accessed January 24, 2011.
3. Mattioli D. Firms feel pain from health law. WSJ. December 13, 2010. Available at: http://online.wsj.com/article/SB10001424052748703727804576011791786531256.html. Accessed December 13, 2010.
4. The Kaiser Family Foundation and Health Research & Educational Trust. Employer Health Benefits 2010 Annual Survey. Available at: http://ehbs.kff.org/pdf/2010/8085.pdf. Accessed November 23, 2010.
5. Fairman KA, Curtiss FR. Selling real-world health care research to reluctant buyers: evidence-based education or marketing a defective product? J Manag Care Pharm. 2009;15(3):294-96. Available at: http://www.amcp.org/data/jmcp/294-296.pdf. Accessed November 23, 2010.
6. De Brantes F, Wickland PS, Williams JP. The value of ambulatory care measures: a review of clinical and financial impact from an employer/payer perspective. Am J Manag Care. 2008;14(6):360-68. Available at: http://www.ajmc.com/media/pdf/AJMC_08jun_Brantes360to68.pdf. Accessed November 23, 2010.
7. Lee DH, Vielemeyer O. Analysis of overall level of evidence behind Infectious Diseases Society of America practice guidelines. Arch Intern Med. 2011;171(1):18-22.
8. Fairman KA, Curtiss FR. Still looking for health outcomes in all the wrong places? Misinterpreted observational evidence, medication adherence promotion, and value-based insurance design. J Manag Care Pharm. 2009;15(6):501-07. Available at: http://www.amcp.org/data/jmcp/501-507.pdf.
9. Motheral B. Value-based insurance design: a bargain at $10 per day? Rx Outcomes Adviser. December 15, 2010. Available at: http://rxoutcomesadviser.wordpress.com/2010/12/15/value-based-insurance-design-a-bargain-at-10-per-day/. Accessed January 24, 2011.
10. Motheral B. About Rx Outcomes Adviser. Available at: http://rxoutcomesadviser.wordpress.com/about/. Accessed January 24, 2011.
11. Choudhry NK, Rosenthal MB, Milstein A. Assessing the evidence for value-based insurance design. Health Aff (Millwood). 2010;29(11):1988-94.
12. Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001;7(9):861-67. Available at: http://www.ajmc.com/media/pdf/AJMC2001sepFendrick861_867.pdf. Accessed January 24, 2011.
13. University of Michigan, Center for Value-Based Insurance Design. Funding. Available at: http://www.sph.umich.edu/vbidcenter/about/funding.html. Accessed January 24, 2011.
14. Fendrick AM, Edlin ML. Value-based insurance design landscape digest. National Pharmaceutical Council. July 2009. Available at: http://www.vbhealth.org/wp-content/uploads/2009/08/NPC_VBIDreport_7-22-09.pdf. Accessed December 10, 2010.
15. University of Michigan Department of Public Relations and Marketing Communications. The co-pay connection: lowering drug co-pays for chronic disease patients increases use of important preventive medicines, rigorous study shows. January 8, 2008. Available at: http://www.med.umich.edu/opm/newspage/2008/drugcopay.htm. Accessed January 23, 2011.
16. Fuhrmans V. New tack on copays: cutting them. WSJ. May 8, 2007:D1. Available at: http://www.sph.umich.edu/vbidcenter/news/pdfs/WSJ%20Copays%20May%208%20(2).pdf. Accessed January 25, 2011.
17. Hensley S. Chopping copays makes medicines more attractive. NPR. November 2, 2010. Available at: http://www.npr.org/blogs/health/2010/11/02/130998493/chopping-copays-makes-statins-plavix-moreattractive. Accessed January 24, 2011.
18. National Business Group on Health/Towers Watson. Raising the bar on health care: moving beyond incremental change. 2010. Available at: http://www.towerswatson.com/assets/pdf/1345/TW_15565_NBGH.pdf. Accessed January 24, 2011.
19. Andrews M. doctors play crucial role in tying health care choices to value. Shots-NPR's Health Blog. November 30, 2010. Available at: http://www.npr.org/blogs/health/2010/11/30/131690967/doctors-play-crucial-rolein-tying-health-care-choices-to-value. Accessed January 24, 2011.
20. Blanton K. Health care: spend more, save more. CFO.com. November 18, 2010. Available at: http://www.cfo.com/article.cfm/14540665/c_14540734. Accessed December 10, 2010.
21. Kertesz L. Economic problems put brakes on Rx copay waiver trend: senior management wait for more evidence of health care savings. Business Insurance. May 11, 2009. Available at: http://www.businessinsurance.com/apps/pbcs.dll/article?AID=9999100027607&template=printart. Accessed February 12, 2011.
22. Anonymous. Health benefit cost growth accelerates to 6.9% in 2010. Mercer. November 17, 2010. Available at: http://www.mercer.com/pressreleases/1400235. Accessed December 10, 2010.
23. Reinke T. Large PBMs transform old business models. Manag Care. 2009;18(10):20-21, 25-28. Available at: http://www.managedcaremag.com/archives/0910/0910.pbms.html. Accessed December 14, 2010.
24. Medco. 2010 drug trend report: Solving the healthcare cost/quality equation. Available at: http://www.drugtrend.com/art/drug_trend/pdf/DT_Report_2010.pdf. Accessed December 14, 2010.
25. Walgreens Health Initiatives. Pharmacy benefit solutions: 2010 trend report. Available at: http://www.walgreenshealth.com/pdf/newsletterreport/PBS12843_TrendReport_web2.pdf. Accessed December 14, 2010.
26. Miller S, Cox E, Nease B, et al. 2009 Drug trend report: solving for America's $163 billion in pharmacy-related waste. April 2010. Available at: http://www.express-scripts.com/research/studies/drugtrendreport/2009/dtrFinal.pdf. Accessed January 24, 2011.
27. Lofberg P, Brennan T, Greer L, et al. Insights 2010: evolving pharmacy care. Available at: https://www.caremark.com/portal/asset/CVSCaremark_Insights_2010.pdf. Accessed January 24, 2011.
28. Prime Therapeutics. 2010 drug trend insights: where smart pharmacy benefit management meets results. Available at: http://www.primetherapeutics.com/pdf/2010primedrugtrends.pdf. Accessed January 24, 2011.
29. Chang A, Liberman JN, Coulen C, Berger JE, Brennan TA. Value-based insurance design and antidiabetic medication adherence. The American Journal of Pharmacy Benefits. 2010;2(1):39-45.
30. Gleason PP, Starner CI, Gunderson BW, Schafer JA, Sarran HS. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm. 2009;15(8). Available at: http://www.amcp.org/data/jmcp/648-658.pdf.
31. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30(1):91-98.
32. Fairman KA. What pharmacy benefit designers need to know about perception and reality: never forget the elephant in the pharmacy. J Manag Care Pharm. 2008;14(4):387-94. Available at: http://www.amcp.org/data/jmcp/JMCPMaga_387-394.pdf.
33. Fitch K, Iwasaki K, Pyenson B. Value-based insurance designs for diabetes drug therapy: actuarial and implementation considerations. Prepared for Takeda Pharmaceuticals, North America, Inc., by Milliman. December 1, 2008. Available at: http://publications.milliman.com/research/health-rr/pdfs/vbid-diabetes-drug-therapy-RR12-01-08.pdf. Accessed January 24, 2011.
34. Federal Trade Commission. FTC issues report on PBM ownership of mail-order pharmacies. September 6, 2005. Available at: http://www.ftc.gov/opa/2005/09/pharmbenefit.shtm. Accessed February 7, 2011.
35. Doru OK, Schmittdiel JA, Dyer WT, et al. Mail-order pharmacy use and adherence to diabetes-related medications. Am J Manag Care. 2010;16(1):33-40. Available at: http://www.ajmc.com/media/pdf/AJMC_2010Jan_Duru_33to40.pdf. Accessed December 16, 2010.
36. Devine S, Vlahiotis A, Sundar H. A comparison of diabetes medication adherence and healthcare costs in patients using mail order pharmacy and retail pharmacy. J Med Econ. 2010;13(2):203-11.
37. Brown TA, Rickles NM. Mail-order versus local pharmacies on adherence: study methods make for unfair comparison [letter and author reply]. Am J Manag Care. 2010;16(3):226-28. Available at: http://www.ajmc.com/media/pdf/AJMC_2010marLtrToEd_226to228.pdf. Accessed December 16, 2010.
38. Matchar DB, McCrory DC, Orlando LA, et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists (ARBs) for treating essential hypertension. November 2007. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/12/45/ACEI_ARBFullReport.pdf. Accessed January 13, 2011.
39. Bolen S, Wilson L, Vassy J, et al. Comparative effectiveness and safety of oral diabetes medications for adults with type 2 diabetes. Agency for Healthcare Research and Quality. July 2007. Available at: http://www.effectivehealthcare.ahrq.gov/repFiles/OralFullReport.pdf. Accessed January 13, 2011.
40. Choudhry NK, Shrank WH. Four dollar generics-increased accessibility, impaired quality assurance. N Engl J Med. 2010;363(20):1885-87. Available at: http://www.nejm.org/doi/full/10.1056/NEJMp1011625. Accessed January 25, 2011.
41. Fendrick AM, Smith DG, Chernew ME. Applying value-based insurance design to low-value health services. Health Aff (Millwood). 2010;29(11):2017-21.
42. Melnick SJ, Motheral BR. Is "value-based" value wasted? Examining value-based insurance designs through the lens of cost-effectiveness. J Manag Care Pharm. 2010;16(2):130-33. Available at: http://www.amcp.org/data/jmcp/130-133.pdf.
43. Chernew ME, Juster IA, Shah M, et al. Evidence that value-based insurance can be effective. Health Aff (Millwood). 2010;29(3):530-36.
44. Robinson JC. Applying value-based insurance design to high-cost health services. Health Aff (Millwood). 2010;29(11):2009-16.
45. U.S. Preventive Services Task Force. Screening for breast cancer. November 2009, updated July 2010. Available at: http://www.uspreventiveservicestaskforce.org/uspstf/uspsbrca.htm. Accessed January 25, 2011.
46. Hobson K. Prevention task force cancels Nov. meeting; would have included prostate screening vote. WSJ Health Blog. October 26, 2010. Available at: http://blogs.wsj.com/health/2010/10/26/prevention-taskforce-cancels-nov-meeting-would-have-included-prostate-screening-vote/. Accessed January 25, 2011.
47. American Cancer Society. Breast awareness and self-exam. September 15, 2010, revised January 4, 2011. Available at: http://www.cancer.org/Cancer/BreastCancer/MoreInformation/BreastCancerEarlyDetection/breastcancer-early-detection-acs-recs-bse. Accessed January 25, 2011.
48. American Cancer Society. American Cancer Society recommendations for prostate cancer early detection. December 1, 2010. Available at: http://www.cancer.org/Cancer/ProstateCancer/MoreInformation/ProstateCancerEarlyDetection/prostate-cancer-early-detection-acs-recommendations. Accessed January 25, 2011.
49. Brawley OW, Gansler T. Introducing the 2010 American Cancer Society prostate cancer screening guideline. CA Cancer J Clin. 2010;60(2):68-69. Available at: http://caonline.amcancersoc.org/cgi/reprint/60/2/68. Accessed January 25, 2011.
50. U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151(10):716-26. Available at: http://www.uspreventiveservicestaskforce.org/uspstf09/breastcancer/brcanrs.pdf. Accessed January 25, 2011.
51. American Cancer Society. American Cancer Society guidelines for the early detection of cancer. Available at: http://www.cancer.org/Healthy/FindCancerEarly/CancerScreeningGuidelines/american-cancer-societyguidelines-for-the-early-detection-of-cancer. Accessed January 25, 2011.
52. American College of Radiology. Detailed ACR statement on ill advised and dangerous USPSTF mammography recommendations. Undated document. Available at: http://www.acr.org/MainMenuCategories/media_room/FeaturedCategories/PressReleases/UPSTFDetails.aspx. Accessed January 6, 2011.
53. Harris G. F.D.A to restrict Avandia, citing heart risk. NY Times. September 23, 2010. Available at: http://www.nytimes.com/2010/09/24/health/policy/24avandia.html?_r=2. Accessed January 25, 2011.
54. U.S. Food and Drug Administration. FDA significantly restricts access to the diabetes drug Avandia. September 23, 2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226975.htm. Accessed January 25, 2011.
55. Appleby J. Carrot-and-stick health plans aim to cut costs: potentially controversial policies are part of trend toward 'value-based design.' Kaiser Health News. March 11, 2010. Available at: http://www.kaiserhealthnews.org/Stories/2010/March/11/value-based-health-insurance.aspx. Accessed January 25, 2011.
56. Kapowich JM. Oregon's test of value-based insurance design in coverage for state workers. Health Aff (Millwood). 2010;29(11):2028-32.
57. Fairman KA, Curtiss FR. Making the world safe for evidence-based policy: let's slay the biases in research on value-based insurance design. J Manag Care Pharm. 2008;14(2):198-204. Available at: http://www.amcp.org/data/jmcp/JMCPMaga_March%2008_198-204.pdf.
58. Fairman KA. The future of prescription drug cost-sharing: real progress or dropped opportunity? J Manag Care Pharm. 2008;14(1):70-82. Available at: http://www.amcp.org/data/jmcp/JMCPMaga_JanFeb%2008_070-082.pdf.
59. Fairman KA, Motheral BR, Henderson RR. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Ther. 2003;25(12):3147-66.
60. Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39(12):1293-304.
61. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224-32. Available at: http://www.nejm.org/doi/full/10.1056/NEJMsa030954.
62. Sedjo RL, Cox ER. Lowering copayments: impact of simvastatin patent expiration on patient adherence. Am J Manag Care. 2008;14(12):813-18. Available at: http://www.ajmc.com/media/pdf/AJMC_08dec_Sedjo_813to818.pdf. Accessed December 28, 2010.
63. Maciejewski ML, Farley JF, Parker J, Wansink D. Copayment reductions generate greater medication adherence in targeted patients. Health Aff (Millwood). 2010;29(11):2002-08.
64. Chernew ME, Newhouse JP. What does the RAND Health Insurance Experiment tell us about the impact of patient cost sharing on health outcomes? Am J Manag Care. 2008;14(7):412-14. Available at: http://www.ajmc.com/media/pdf/AJMC_08jul_Chernew_412to414_.pdf. Accessed January 23, 2011.
65. Manning WG, Newhouse JP, Duan N, Keeler EB, Liebowitz A, Marquis MS. Health insurance and the demand for medical care: evidence from a randomized experiment. Am Econ Rev. 1987;77(3):251-77.
66. Brook RH, Ware JE, Rogers WH, et al. The effect of coinsurance on the health of adults: results from the Rand Health Insurance Experiment. The Rand Corporation. R-3055-HHS. 1984. Available at: http://www.rand.org/pubs/reports/R3055.html. Accessed February 9, 2011.
67. Keeler EB. Effects on cost sharing on use of medical services and health. J Med Pract Manage. 1992;8:317-21. Available at: http://www.rand.org/content/dam/rand/pubs/reprints/2005/RP1114.pdf. Accessed February 7, 2011.
68. Choudhry NK, Fischer MA, Avorn J, et al. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood). 2010;29(11):1995-2001.
69. Zeng F, An JJ, Scully R, Barrington C, Patel BV, Nichol MB. The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation. Value Health. 2010;13(6):846-52.
70. Gibson TB, Wang S, Kelly E, et al. A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses. Health Aff (Millwood). 2011;30(1):109-17.
71. Gibson TB, Mahoney J, Ranghell K, Cherney BJ, McElwee N. Valuebased insurance plus disease management increased medication use and produced savings. Health Aff (Millwood). 2011;30(1):100-08.
72. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147:W-163-W-194. Available at: http://www.annals.org/cgi/reprint/147/8/W-163.pdf. Accessed January 15, 2011.
73. National Cholesterol Education Program. ATP III guidelines at-a-glance quick desk reference. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf. Accessed January 15, 2011.
74. U.S. Department of Health and Human Services, National High Blood Pressure Education Program. JNC 7 express: the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. December 2003. Available at: http://www.nhlbi.nih.gov/guidelines/hypertension/express.pdf. Accessed January 15, 2011.
75. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32(1):193-203. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606813/pdf/193.pdf. Accessed January 15, 2011.
76. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation. 2009;119(15):2051-57. Available at: http://circ.ahajournals.org/cgi/reprint/119/15/2051. Accessed January 18, 2011.
77. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005;11(5 Suppl):S170-S176. Available at: http://www.ajmc.com/media/pdf/A128_05augMahoneyS170to176.pdf. Accessed December 10, 2010.
78. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood). 2008;27(1):103-12.
79. Andrews RM. The national hospital bill: the most expensive conditions by payer, 2006. HCUP statistical brief #59. September 2008. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb59.pdf. Accessed January 17, 2011.
80. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med. 2008;359(21):2195-207. Published online ahead of print on Nov 9, 2008. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa0807646. Accessed January 23, 2011.
81. Anonymous. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339(19):1349-57. Available at: http://www.nejm.org/doi/full/10.1056/NEJM199811053391902. Accessed January 24, 2011.
82. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78.
83. Spaulding A, Fendrick AM, Herman WH, et al. A controlled trial of value-based insurance design-the MHealthy: Focus on Diabetes (FOD) trial. Implement Sci. 2009;4:19. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673203/pdf/1748-5908-4-19.pdf. Accessed January 18, 2011.
84. n, where C=cumulative probability, a = single-test alpha, and n=number of tests.
85. Kaul S, Diamond GA. Trial and error. How to avoid commonly encountered limitations of published clinical trials. J Am Coll Cardiol. 2010;55(5):415-27.
86. Choudhry NK, Brennan T, Toscano M, et al. Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies. Am Heart J. 2008;156(1):31-36. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697130/pdf/nihms78751.pdf. Accessed January 18, 2011.
87. Fairman KA. Accuracy in pharmacoeconomic literature review: lessons learned from the Navajo Code Talkers. J Manag Care Pharm. 2008;14(9):886-91. Available at: http://www.amcp.org/data/jmcp/886-891.pdf.
88. Motheral BR. Pharmaceutical step-therapy interventions: a critical review of the literature. J Manag Care Pharm. 2011;17(2):143-55. Available at: http://www.amcp.org/data/jmcp/143-155.pdf.